Previous 10 | Next 10 |
2023-12-14 09:57:42 ET DENVER, Colo., Dec. 14, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Freight Technologies Inc (NASDAQ: FRGT), ZyVersa Therapeutics Inc (NASDAQ: ZVSA), Esperion Therapeutics Inc (...
2023-12-13 16:27:44 ET More on Esperion Therapeutics Esperion: Navigating The 'Bemp' Of Success Amidst Market Waves And Legal Tides Esperion Therapeutics, Inc. (ESPR) Q3 2023 Earnings Call Transcript Esperion Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Prese...
– Updated Label Adds Primary Hyperlipidemia, Removes Maximally Tolerated Statin Requirement, Removes Limitation of Use – – Cardiovascular (CV) Risk Reduction Labels Remain on Track: in U.S. with PDUFA Date of March 31; in Europe with Anticipated Approval in 1H 2024 ...
2023-11-25 16:32:53 ET More on BioCryst Pharmaceuticals, Crinetics Pharmaceuticals, etc. Mirum Pharmaceuticals, Inc. (MIRM) Q3 2023 Earnings Call Transcript BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2023 Earnings Call Transcript Immunocore: First Half Of 2024 IMC-F106...
– A Prespecified, Exploratory Analysis of Participants Reports Those with Higher Baseline Inflammation More Likely to Experience a Major Cardiovascular Event (MACE), Cardiovascular Death, and All-Cause Mortality Compared to Those with the Lowest Inflammation – ȁ...
2023-11-12 22:45:00 ET Summary Esperion Therapeutics reports strong Q3 earnings for bempedoic acid, with revenues of $20.3M and impressive growth in retail Rx and new-to-brand prescriptions. Anticipated label expansion in the US and EU in 2024 could significantly broaden bempedoic...
– Data from Randomized Control Trial Will Advance Evidence for Evaluation and Treatment of Heart Disease by Studying Actual Disease: Atherosclerosis – ANN ARBOR, Mich., Nov. 11, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced participation in the TRANSFORM trial at ...
2023-11-07 13:30:05 ET Esperion Therapeutics, Inc. (ESPR) Q3 2023 Earnings Conference Call November 07, 2023 08:00 AM ET Company Participants Alexis Callahan - Head of Investor Relations Sheldon Koenig - President & Chief Executive Officer Ben Halladay - Chie...
2023-11-07 06:03:41 ET More on Esperion Therapeutics Esperion Therapeutics: Speculative Buy, Playing The $300 Million Milestone Litigation Esperion gains on new data for cholesterol-lowering agent Seeking Alpha’s Quant Rating on Esperion Therapeutics H...
Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
ANN ARBOR, Mich., July 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2024 financial results before the market opens on Monday, August 12, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financi...
ANN ARBOR, Mich., July 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the BTIG Biotech Conference on Monday, August 5, 2024, at 4 p.m. ET. Esperion Therapeutics At Esperion, we discover, develop, and commercialize innovat...
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) – – Animated Characters Are a Visual Representation of An Unseen Risk “Lurking” In Patients’ Artery Walls &...